sellWeak
Thomas Gad sold $57k of YMAB
CHIEF BUSINESS OFFICER at Y-mAbs Therapeutics, Inc.. 10,810 shares at an average of $5.23, traded Mar 7, 2025, filed Mar 11, 2025.
Warning score
22Value
$57k
10,810 shares
Holdings after
202,721
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +7Trade size$57k at market
- 0Share of holdings soldSold 5.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-007737, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 7, 2025 | SOpen-market sale Common Stock | -10,810 | $5.23 | $57k | 202,721 | Mar 11, 2025 |
Related signals
Other insiders at Y-mAbs Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $64k 3,900 shares | -2% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Vignesh Rajah SVP & CHIEF MEDICAL OFFICER | $28k 1,711 shares | -5% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER | $28k 1,682 shares | -5% | |
| 50Moderate | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad Chief Business Officer | $1.0M 150,000 shares | -36% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $44k 6,455 shares | +0% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Johan Wedell-Wedellsborg director | $44k 6,455 shares | +0% | |
| 51Moderate | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $890k 127,549 shares | +3% | |
| 51Moderate | Y-mAbs Therapeutics, Inc. | Johan Wedell-Wedellsborg director | $890k 127,549 shares | +3% | |
| 42Moderate | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $309k 51,837 shares | +1% | |
| 42Moderate | Y-mAbs Therapeutics, Inc. | Johan Wedell-Wedellsborg director | $309k 51,837 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.